Jove
Visualize
Contact Us

Related Concept Videos

Asthma I: Introduction01:28

Asthma I: Introduction

Asthma is a chronic inflammatory disorder of the airways characterized by variable airflow obstruction and heightened bronchial responsiveness to a wide range of triggers. The underlying inflammation leads to airway swelling, mucus hypersecretion, and smooth muscle constriction, all of which narrow the airway lumen and impede airflow. Clinically, asthma presents with recurrent episodes of wheezing, shortness of breath, chest tightness, and coughing, symptoms that typically vary in intensity and...
Asthma: Pathogenesis and Management01:20

Asthma: Pathogenesis and Management

Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
Asthma-II: Pathophysiology and Classification01:26

Asthma-II: Pathophysiology and Classification

Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs01:25

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Esophageal Achalasia01:27

Esophageal Achalasia

Esophageal achalasia is a chronic neurogenic disorder characterized by impaired relaxation of the lower esophageal sphincter (LES) and absent or ineffective peristalsis in the distal esophagus. This leads to a functional obstruction without a physical blockage, despite significant disruption of esophageal motility.EtiologyAchalasia is caused by degeneration of the myenteric (Auerbach's) plexus, specifically the loss of inhibitory ganglion cells that produce vasoactive intestinal peptide (VIP)...
Drugs Used in Lower Respiratory Disorders: Overview01:17

Drugs Used in Lower Respiratory Disorders: Overview

Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cancer history and second cancer risk in polycythemia vera and essential thrombocythemia.

Blood cancer journal·2026
Same author

ICC/WHO-Defined and NGS-Annotated Idiopathic Hypereosinophilia (iHES/iHE): Mutations, Clinical and Treatment Details, and Predictors of Survival.

American journal of hematology·2026
Same author

Systemic Mastocytosis in Adults: 2026 Update on Diagnosis, Risk Stratification and Management.

American journal of hematology·2026
Same author

Distinct Longitudinal Patterns of Basal and Squamous Cell Carcinoma in Polycythemia Vera and Essential Thrombocythemia.

American journal of hematology·2026
Same author

<i>CSF3R</i>-mutated chronic neutrophilic leukemia: a two-center study of 44 consecutive patients.

Haematologica·2026
Same author

Autoimmune and Inflammatory Diseases in Polycythemia Vera and Essential Thrombocythemia: Impact on Disease Outcomes and Comorbidities.

American journal of hematology·2026
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Jun 13, 2026

Three-Dimensional Cell Culture Models to Investigate the Epithelial Barrier in Eosinophilic Esophagitis
03:23

Three-Dimensional Cell Culture Models to Investigate the Epithelial Barrier in Eosinophilic Esophagitis

Published on: May 10, 2024

Primary eosinophilic disorders: a concise review.

Animesh Pardanani1, Ayalew Tefferi

  • 1Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA.

Current Hematologic Malignancy Reports
|April 29, 2010
PubMed
Summary

Hypereosinophilic syndrome (HES) and chronic eosinophilic leukemia (CEL-NOC) are distinct from PDGFR-mutated disorders. Imatinib effectively treats PDGFR-mutated eosinophilic neoplasms, unlike other HES/CEL-NOC cases.

Area of Science:

  • Hematology
  • Oncology
  • Molecular Biology

Background:

  • Primary eosinophilic disorders encompass hypereosinophilic syndrome (HES), chronic eosinophilic leukemia (CEL-NOC), and PDGFR-rearranged myeloid neoplasms.
  • WHO criteria distinguish HES by the absence of clonal markers, while CEL-NOC presents with HES-like features and abnormal karyotypes or excess blasts.

Purpose of the Study:

  • To clarify the distinctions between HES, CEL-NOC, and molecularly defined eosinophilic disorders.
  • To highlight the therapeutic implications of these distinctions, particularly regarding imatinib treatment.

Main Methods:

  • Review of World Health Organization (WHO) consensus criteria for diagnosing HES and CEL-NOC.
  • Comparison of diagnostic criteria and treatment responses for different eosinophilic disorders.

More Related Videos

Methodology for Sputum Induction and Laboratory Processing
13:28

Methodology for Sputum Induction and Laboratory Processing

Published on: December 17, 2017

Related Experiment Videos

Last Updated: Jun 13, 2026

Three-Dimensional Cell Culture Models to Investigate the Epithelial Barrier in Eosinophilic Esophagitis
03:23

Three-Dimensional Cell Culture Models to Investigate the Epithelial Barrier in Eosinophilic Esophagitis

Published on: May 10, 2024

Methodology for Sputum Induction and Laboratory Processing
13:28

Methodology for Sputum Induction and Laboratory Processing

Published on: December 17, 2017

Main Results:

  • HES and CEL-NOC are differentiated from PDGFR-mutated eosinophilic neoplasms.
  • PDGFR-mutated disorders show significant response to imatinib, unlike other eosinophilic neoplasms.
  • Current HES management involves observation, corticosteroids, or steroid-sparing agents; investigational drugs are used for refractory cases with limited long-term data.

Conclusions:

  • Accurate classification of eosinophilic disorders is crucial for targeted therapy.
  • Imatinib represents a key therapeutic option for PDGFR-mutated eosinophilic neoplasms.
  • Further research is needed on the long-term efficacy and safety of investigational treatments for refractory HES.